Laekna's Cancer Drug Opatisumimab Earns Late-Breaking Abstract Status at ESMO Congress

Laekna (09887.HK) announced that its pivotal Phase IIb clinical trial for the investigational drug opatisumimab has been selected as a Late-Breaking Abstract (LBA) for a proffered oral presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The selection highlights the potential clinical significance of the study, which evaluates the drug as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).

Key Study Details

The LBA designation is reserved by ESMO for studies with high-impact, potentially practice-changing data. The trial is a key registrational study intended to support future New Drug Application (NDA) submissions to regulatory agencies, according to the company's statement.

The study evaluates the efficacy and safety of opatisumimab, a novel PD-L1x4-1BB bispecific antibody, in patients with advanced EP-NEC who have previously received at least two lines of systemic therapy. The presentation will be delivered by Director Ming Lu from Peking University Cancer Hospital, where Professor Lin Shen serves as the principal investigator.

Broad Pipeline Recognition

In addition to the LBA selection, Laekna secured two other proffered oral presentation slots at the prestigious oncology conference, underscoring the strength of its clinical development pipeline. Proffered oral presentations are among the highest-level presentation categories at ESMO, granted to original research of exceptional quality.

Ad

The three studies accepted for oral presentation are:

• The pivotal Phase IIb study of opatisumimab monotherapy in late-stage EP-NEC (the LBA).
• A Phase Ib/II study of opatisumimab combined with chemotherapy as a first-line treatment for EP-NEC.
• A Phase I study of LBL-034 for treating relapsed or refractory multiple myeloma (RRMM).

Market Implications

The multiple high-profile acceptances at ESMO provide significant validation for Laekna's research and development capabilities on an international stage. For investors, this signals progress in the company's clinical pipeline, particularly for its lead asset, opatisumimab, in a hard-to-treat cancer indication. Positive data from the LBA presentation could be a significant catalyst for the company.

Laekna also noted that four additional studies were accepted for poster presentations, covering research on opatisumimab in biliary tract cancer (BTC), its mechanism in microsatellite stable colorectal cancer, and several meta-analyses.